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Nicotine is the primary psychoactive and addictive com-
ponent of tobacco smoke. It is interesting to note that higher 
incidences of tobacco dependence and difficulty quitting 
are reported in clinical populations (Morris, Giese, Turn-
bull, Dickinson, & Johnson-Nagel, 2006; Williams & Ziedo-
nis, 2004). For example, tobacco dependence commonly co-
occurs in schizophrenic populations (de Leon & Diaz, 2005) 
and is highly correlated with mood disorders (Glassman et 
al., 1990; Pomerleau, Marks, & Pomerleau, 2000). Recent re-
ports show that people diagnosed with attention-deficit/hyper-
activity disorder (ADHD) are twice as likely to become smok-
ers than their peers (Milberger, Biederman, Faraone, Chen, & 
Jones, 1997; A. S. Potter & Newhouse, 2004) and show more 
severe withdrawal symptoms when trying to quit tobacco use 
(Pomerleau et al., 2003). Thus, the abuse liability of nicotine 
appears exacerbated in ADHD patients. Therefore, pharmaco-
therapies simultaneously targeting ADHD symptoms and nic-
otine addiction may have some treatment utility for this clini-
cal subpopulation.
Three drugs commonly prescribed to treat ADHD are meth-
ylphenidate, bupropion, and atomoxetine (Ritalin, Wellbutrin, 
and Strattera, respectively). Of these drugs, bupropion and 
methylphenidate increase dopamine release in brain reward 
pathways (Ascher et al., 1995; Bymaster et al., 2002; Kuczen-
ski & Segal, 1997; Nomikos, Damsma, Wenkstern, & Fibiger, 
1992). Bupropion has lower affinity for the dopamine trans-
porter than methylphenidate and also blocks norepineph-
rine reuptake (Ascher et al., 1995; Katz, Izenwasser, & Terry, 
2000). Atomoxetine, on the other hand, acts primarily on the 
noradrenergic system by blocking the reuptake of synaptic 
norepinephrine (Bymaster et al., 2002). Drugs targeting the 
noradrenergic system may benefit patients with ADHD who 
are also smokers given that atomoxetine has impacted nico-
tine-induced responding in prior research. Specifically, Gould, 
Rukstalis, and Lewis (2005) demonstrated that an acute ad-
ministration of nicotine (0.125 mg/kg) or atomoxetine (2 mg/
kg) enhanced prepulse inhibition of the acoustic startle re-
sponse in mice. However, this enhancement was blocked 
when atomoxetine was administered before nicotine, probably 
owing to overactivation of the noradrenergic system (Gould et 
al., 2005). Atomoxetine also alleviates attention deficits asso-
ciated with nicotine withdrawal. For example, mice undergo-
ing nicotine withdrawal show impaired contextual fear condi-
tioning in comparison to mice in a control condition (Davis & 
Gould, 2007; Davis, James, Siegel, & Gould, 2005). This im-
pairment was reversed by an acute injection of atomoxetine 
(Davis & Gould, 2007).
Current theories of tobacco abuse attribute associative 
learning processes as having a prominent role in the acquisi-
tion, maintenance, and/or relapse of drug use and abuse (e.g., 
Bevins & Palmatier, 2004; Di Chiara, 1999; Geier, Mucha, 
&  Pauli, 2000; Lazev, Herzog, & Brandon, 1999; Pritchard, 
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Abstract: People diagnosed with attention-deficit/hyperactivity disorder (ADHD) are at an increased risk to start smoking and have 
greater difficulty quitting. Nicotine, one of the principal addictive components of tobacco smoke, functioned as a conditioned stimu-
lus (CS) for intermittent sucrose delivery in a Pavlovian drug discrimination task with rats. This study compared the ability of com-
monly prescribed ADHD medications (i.e., methylphenidate, atomoxetine, and bupropion) and additional dopamine reuptake inhib-
itors (i.e., cocaine and GBR 12909) to substitute for the CS effects of nicotine. Atomoxetine was also used to antagonize these CS 
effects. Rats acquired the discrimination as evidenced by increased dipper entries in nicotine (0.2 mg base/kg) sessions as compared 
with saline sessions. Nicotine generalization was dose dependent. Bupropion (10 and 20 mg/kg), methylphenidate (10 mg/kg), and 
cocaine (5 and 10 mg/kg) partially substituted for the 0.2 mg/kg nicotine CS. Atomoxetine did not substitute for the nicotine CS; 
however, atomoxetine (1 to 10 mg/kg) partially blocked nicotine’s CS effects. These results suggest that atomoxetine, bupropion, 
and/or methylphenidate may be effective treatments for people diagnosed with ADHD and addicted to nicotine.
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Robinson, Guy, Davis, & Stiles, 1996; Rose & Levin, 1991). 
In the case of nicotine conditioning, environmental cues (con-
ditioned stimulus, CS) presented in close temporal proxim-
ity with the physiological effects of the drug (unconditioned 
stimulus, US) come to evoke behavioral and cognitive re-
sponses even in a non–drug state. From this framework, the 
interoceptive effects of nicotine are functioning as a US. In-
deed, this framework is the most commonly used to study the 
potential conditioning processes contributing to nicotine use 
(see Bevins & Palmatier, 2004, for a review). Research from 
our laboratory and others has extended this conceptualization 
to include nicotine as an interoceptive CS (Besheer, Palma-
tier, Metschke, & Bevins, 2004; Bevins, Penrod, & Reichel, 
2007; Clements, Glautier, Stolerman, White, & Taylor, 1996; 
Murray & Bevins, 2007; Troisi, 2006; Wilkinson et al., 2006). 
In our research, to train nicotine as a CS, rats had intermit-
tent access to sucrose on nicotine sessions; on intermixed sa-
line sessions no sucrose was present. Conditioned responding 
to the nicotine CS was evidenced by more head entries into 
the dipper receptacle before the first sucrose delivery on nico-
tine sessions (often termed goal tracking; Boakes, 1977; Far-
well & Ayres, 1979) than in a comparable time period on sa-
line sessions (Besheer et al., 2004; Bevins et al., 2007; Murray 
& Bevins, 2007; Wilkinson et al., 2006).
To date, bupropion is the only drug approved for the treat-
ment of ADHD that has been tested for substitution of the 
interoceptive CS effects of nicotine. In brief, when 0.4 mg/
kg nicotine was trained as a CS, 20 mg/kg bupropion in-
creased conditioned responding above saline levels, but not 
quite equivalent to nicotine CS levels, suggesting that bupro-
pion produces an interoceptive cue somewhat similar to nico-
tine (Besheer et al., 2004). Therefore, one purpose of the pres-
ent study was to extend this research by determining whether 
the widely prescribed ADHD medications bupropion, methyl-
phenidate, and atomoxetine substituted for a more moderate 
dose of nicotine (i.e., 0.2 mg/kg) functioning as a CS. Addi-
tionally, we tested cocaine and GBR 12909 (highly specific 
dopamine reuptake inhibitor) to determine whether dopamine 
reuptake inhibitors with varying affinity for the transporter 
would substitute for the nicotine CS (Katz et al., 2000). Fi-
nally, prompted by the research of Gould and colleagues de-
scribed earlier, we tested whether atomoxetine would antago-
nize the nicotine-evoked conditioned response (CR).
Method
Subjects
Sixteen male Sprague–Dawley rats (weighing 300 ± 20 g 
at the start of the study) were obtained from Harlan (India-
napolis, IN). The rats had been used in a previous study and 
had experienced 15 consecutive daily exposures to the nico-
tine (0.2 mg/kg) and sucrose (see Bevins et al., 2007, Exper-
iment 2). Animals were housed individually in clear polycar-
bonate tubs lined with wood shavings in a temperature- and 
humidity-controlled colony room. Water was continually pro-
vided in the home cage. Food access was restricted such that 
rats’ body weights were maintained at 85% of their free-feed-
ing weight. Approximately every 30 days, this target weight 
was increased by 2 g. All sessions were conducted during the 
light portion of a 12-hr light–dark cycle. Experimental proto-
cols were approved by the University of Nebraska—Lincoln 
Institutional Animal Care and Use Committee and followed 
the Guide for the Care and Use of Laboratory Animals (Na-
tional Research Council, 1996).
Apparatus
Eight standard conditioning chambers (Med Associates, 
Georgia, VT) were used in this study. Each chamber was en-
closed in a light- and sound-attenuating polyvinyl chloride cu-
bicle fitted with a fan to provide airflow and mask noise. The 
conditioning chambers measured 30.5 × 24.1 × 21 cm (l × w × 
h). The sidewalls were made of aluminum; the ceiling, front, 
and back walls were clear polycarbonate. Each chamber con-
tained a recessed dipper receptacle (5.2 × 5.2 × 3.8 cm; l × 
w × d) in one of the aluminum sidewalls. When the dipper 
arm was raised, it allowed access to 0.1 ml of 26% sucrose so-
lution (wt/vol) in the receptacle. An infrared emitter–detector 
unit located 1.2 cm inside the receptacle and 3 cm from the 
floor recorded head entries. A second infrared emitter–detec-
tor unit bisected the chamber 14.5 cm from the sidewall con-
taining the receptacle and was mounted 4 cm above the rod 
floor. This unit provided a measure of activity in the chamber. 
A personal computer with Med Associates interface and soft-
ware (Med-PC for Windows, Version 4) controlled sucrose de-
liveries and recorded dipper entries and chamber activity.
Drugs
(S)-nicotine hydrogen tartrate, bupropion hydrochloride, 
cocaine hydrochloride, GBR 12909, and methylphenidate 
hydrochloride were purchased from Sigma (St. Louis, MO). 
Atomoxetine hydrochloride was purchased from Tocris Cook-
son (Ellisville, MO). Nicotine, cocaine, bupropion, and meth-
ylphenidate were dissolved in 0.9% saline. All drug doses ex-
cept nicotine are reported as salt form; nicotine is reported as 
base. Nicotine was adjusted to a pH of 7.0 ± 0.2 with a di-
lute NaOH solution. GBR 12909 and atomoxetine were dis-
solved in sterile water. All drugs were injected at a volume of 
1 ml/kg. For substitution drugs, injection route, injection-to-
placement intervals, and doses were based on previous stud-
ies (Besheer et al., 2004; Desai, Barber, & Terry, 2003; Gould 
et al., 2005; Mansbach, Rovetti, & Freedland, 1998; Mattiuz 
et al., 2003).
Acquisition
Rats were injected with nicotine or 0.9% saline 5 min be-
fore placement in the conditioning chamber for 20 min. On 
nicotine sessions, rats had 4 s access to sucrose on 36 sepa-
rate occasions. On intermixed saline sessions, sucrose deliver-
ies were withheld. To decrease the possibility of the rats learn-
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ing to time when a sucrose delivery may occur, we used four 
different computer programs controlling sucrose deliveries. 
Comparable programs were written for saline sessions, with 
4-s “empty” intervals occurring in place of sucrose to ensure 
identical session length. The average time before the first su-
crose delivery (or equivalent time in saline sessions) across 
programs was 137 s, with a range of 124–152 s. Nicotine and 
saline sessions were randomly assigned to each rat so that 
there were no more than two of the same session types in a 
row. This acquisition phase lasted 24 days and consisted of 12 
nicotine and 12 saline sessions.
Testing
Nicotine generalization. Following acquisition training, 
rats entered the nicotine generalization phase. On the first 4 
days of a 5-day cycle, rats received two nicotine and two sa-
line training sessions that were randomly intermixed. These 
sessions were identical to those described for acquisition 
and were used to ensure maintenance of the discrimination. 
On Day 5, a 4-min test session was conducted if discrimi-
nation criteria were met (discussed later). This 5-day testing 
cycle was used for the remainder of the experiment. On test 
days, rats were injected subcutaneously with saline or nicotine 
(0.025, 0.1, 0.2, or 0.3 mg/kg) 5 min before chamber place-
ment. Rats were tested on all doses, and the order was ran-
domly assigned for each rat.
Substitution. Upon completion of the nicotine generaliza-
tion phase, rats started the substitution testing phase. On a 
given test day, rats were injected intraperitoneally with bupro-
pion (5, 10, or 20 mg/kg), cocaine (1, 5, 10, or 20 mg/kg), 
GBR 12909 (1, 5, 10, 20, or 30 mg/kg), methylphenidate (1, 
5, or 10 mg/kg), or atomoxetine (0.3, 1, 3, or 10 mg/kg) 15 
min before placement in the chamber. Testing of these drugs 
was intermixed, and the order of drug dose was randomly as-
signed for each rat. Methylphenidate was tested after comple-
tion of all of the other test compounds.
Atomoxetine antagonism. Following substitution testing, 
we assessed whether pretreatment with atomoxetine would 
block conditioned responding evoked by the nicotine CS. On 
test days, rats were injected with atomoxetine (0.1, 0.3, 1, 3, 
or 10 mg/kg ip) 25 min before nicotine (cf. Gould et al., 2005, 
for comparable injection-to-place interval for antagonism). 
As in training, nicotine was injected 5 min before placement 
in the conditioning chamber. The order of drug dose was ran-
domly assigned for each rat.
Dependent Measures and Testing Criteria
For acquisition and testing, the rate of infrared beam breaks 
in the dipper receptacle per second (i.e., dipper entry rate) be-
fore the first sucrose delivery in the nicotine sessions (or 
equivalent time in the saline and tests sessions) served as the 
main dependent measure. For a rat to qualify to test, during 
the substitution and antagonism phases, the dipper entry rate 
on each nicotine session had to be at least 0.01 dipper entries 
per second higher than on both saline sessions within the four 
training sessions of a 5-day testing cycle (cf. Murray & Bev-
ins, 2007). General chamber activity, defined as the number of 
beam breaks per second during the same time period as dipper 
entries, was also analyzed during acquisition and testing.
Data Analyses
For acquisition training, dipper entries and chamber activ-
ity were analyzed with two-way (Drug [nicotine or saline] × 
Session) repeated measures analyses of variance (ANOVAs); 
Fisher’s protected least significant difference (LSD) tests were 
used for post hoc comparisons. For generalization, substitu-
tion, and antagonism testing phases, dipper entries and cham-
ber activity were analyzed with separate one-way repeated 
measures ANOVAs for each compound. One rat began hav-
ing adverse reactions to the training dose of nicotine and was 
removed from the study before completion of GBR 12909 
and methylphenidate substitution and atomoxetine antago-
nism tests. During substitution testing, bupropion, cocaine, 
GBR 12909, and atomoxetine were randomly intermixed. Ac-
cordingly, the same baseline values for nicotine and saline 
sessions were used for comparison purposes. For these com-
parisons, the baseline values were extracted from the nico-
tine and saline training sessions before testing with 3 mg/kg 
atomoxetine. This procedure allows for a random sample of 
baseline values because all drugs and drug doses were ini-
tially assigned in a random order. Methylphenidate substitu-
tion was added to the experiment after completion of all other 
test drugs. Accordingly, separate baseline values for nicotine 
and saline sessions were extracted before testing with 5 mg/kg 
methylphenidate. Fisher’s protected LSD tests were used for 
post hoc comparisons. Of note, to reduce the Type I error rate, 
post hoc comparisons were conditional on a significant omni-
bus ANOVA. Additionally, these comparisons were limited to 
contrasting each test value with saline. Test doses that were 
significantly different from saline were then compared with 
the nicotine training dose. Full substitution or antagonism was 
declared when doses of the test compound significantly dif-
fered from saline but not from the nicotine training dose. Par-
tial substitution or antagonism was declared when a dose dif-
fered statistically from both saline and the nicotine training 
dose. Statistical significance was set at p < .05 (two tailed) for 
all tests. The median effective dose (ED50) was calculated us-
ing linear regression on doses from the ascending limb of the 
dose–effect function.
Results
Acquisition
Figure 1 illustrates that rats readily acquire the discrimina-
tion between nicotine and saline sessions (left graph). There 
was a main effect of drug, F(1, 15) = 23.61, p < .001, and ses-
sion, F(11, 165) = 5.63, p < .001, and a significant Drug × 
Session interaction, F(11, 165) = 8.63, p < .001. Relative to 
saline sessions, dipper entries were higher on Nicotine Ses-
sions 6 to 12 (Fisher’s LSD = .038). For chamber activity 
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(Figure 1, right graph), there was a significant main effect of 
drug, F(1, 15) = 41.97, p < .001, but not session, F(11, 165) 
= 1.44, p = .16. The Drug × Session interaction was signifi-
cant, F(11, 165) = 1.88, p < .05. Chamber activity was higher 
on Nicotine Sessions 3 to 12 in comparison to saline sessions 
(Fisher’s LSD = .062). 
Generalization and Substitution Testing
Nicotine dose effect. Conditioned responding evoked by 
nicotine was sensitive to test dose (Figure 2, left graph), yield-
ing a dose main effect, F(4, 60) = 17.70, p < .001. Specifically, 
rats had higher levels of dipper entries when tested with 0.1, 
0.2, and 0.3 mg/kg nicotine as compared with saline (Fisher’s 
LSD = .045). Further, dipper entries at the training dose (0.2 
mg/kg) were higher than at 0.025 and 0.3 mg/kg nicotine. The 
ED50 for nicotine was 0.075 mg/kg. Chamber activity (Figure 
2, right graph) increased with nicotine dose, yielding a dose 
main effect, F(4, 60) = 9.72, p < .001; activity on 0.1, 0.2, and 
0.3 mg/kg nicotine was above saline levels (Fisher’s LSD = 
.075). 
Bupropion substitution. Bupropion partially substituted 
for the nicotine CS. Dipper entries (Figure 3A, left graph) in-
creased with bupropion dose, yielding a dose main effect, F(3, 
45) = 9.50, p < .001. Specifically, conditioned responding was 
higher at 10 and 20 mg/kg bupropion as compared with saline 
but remained significantly lower as compared with the train-
ing dose of nicotine (Fisher’s LSD = .039). Chamber activity 
(Figure 3A, right graph) also increased with bupropion dose, 
yielding a dose main effect, F(3, 45) = 10.46, p < .001; 10 
and 20 mg/kg increased activity to a level comparable with 
the nicotine training dose (Fisher’s LSD = .105). 
Cocaine substitution. Cocaine partially substituted for 
the nicotine CS, as dipper entries (Figure 3A, left graph) in-
creased with cocaine dose, yielding a dose main effect, F(4, 
60) = 7.68, p < .001. Specifically, conditioned responding 
Figure 1. Mean (±SEM) dipper entries (left graph) and chamber activity (right graph) for rats (n = 16) 
trained with 0.2 mg/kg nicotine during acquisition. *p < .05 for difference from corresponding saline 
session.
Figure 2. Mean (±SEM) dipper entries (left graph) and chamber activity (right graph) for the nicotine 
dose effect (n = 16). *Significantly different from 0.2 mg/kg nicotine, p < .05. +Significantly different 
from saline, p < .05.
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was increased at 5, 10, and 20 mg/kg cocaine in comparison 
to saline but remained significantly lower in comparison to 
the training dose of nicotine (Fisher’s LSD = .031). Chamber 
activity (Figure 3A, right graph) also increased with cocaine 
dose, yielding a dose main effect, F(4, 60) = 4.63, p < .003; 
5, 10, and 20 mg/kg increased activity to a level comparable 
with the nicotine training dose (Fisher’s LSD = .110).
GBR 12909 substitution. GBR 12909 did not alter dipper 
entry rate (Figure 3A, left graph), F(5, 70) = 1.45, p = .22. 
However, GBR 12909 increased chamber activity (Figure 3A, 
right graph), yielding a dose main effect, F(5, 70) = 4.48, p < 
.001, with 10, 20, and 30 mg/kg increasing activity to a level 
comparable with the nicotine training dose (Fisher’s LSD = 
.086).
Atomoxetine substitution. Dipper entries (Figure 3B, left 
graph) decreased with atomoxetine dose, F(4, 60) = 3.66, p < 
.01. The 10 mg/kg atomoxetine reduced dipper entries in com-
parison to saline and the training dose of nicotine (Fisher’s 
LSD = .022). Chamber activity (Figure 3B, right graph) was 
unaffected by atomoxetine dose, F(4, 60) = 2.03, p = .10.
Methylphenidate substitution. Methylphenidate partially 
substituted for the nicotine CS (Figure 3B, left graph), yield-
ing a dose main effect, F(3, 42) = 2.83, p = .05. Specifically, 
conditioned responding was increased at 10 mg/kg methyl-
phenidate in comparison to saline but remained significantly 
lower in comparison to the training dose of nicotine (Fisher’s 
LSD = .046). Chamber activity (Figure 3B, right graph) also 
increased with methylphenidate dose, yielding a dose main ef-
Figure 3. Mean (±SEM) dipper entries (left graphs) and chamber activity (right graphs) during substi-
tution testing for bupropion (n = 16), cocaine (n = 16), and GBR 12909 (n = 15) are shown in Panel A. 
Panel B shows the dipper entries (±SEM) and activity scores (±SEM) for methylphenidate (n = 15) and 
atomoxetine (n = 16). *Significantly different from 0.2 mg/kg nicotine, p < .05. +Significantly differ-
ent from saline, p < .05.
506 Reichel, linkugel, & Bevins in ExpErimEntal and CliniCal psyChopharmaCology, 15 (2007)
fect, F(4, 60) = 4.63, p < .003, with 5 and 10 mg/kg increasing 
activity to a level comparable with the nicotine training dose 
(Fisher’s LSD = .101).
Atomoxetine antagonism. Atomoxetine pretreatment par-
tially blocked conditioned responding evoked by the nicotine 
CS (Figure 4, left graph), yielding a dose main effect, F(5, 
70) = 11.88, p < .001. Specifically, the nicotine-evoked CR 
was decreased with pretreatment of 1, 3, and 10 mg/kg atom-
oxetine in comparison to vehicle pretreatment (i.e., nicotine 
training dose) but remained significantly higher in comparison 
to the saline baseline (Fisher’s LSD = .046). Chamber activ-
ity (Figure 3B, right graph) decreased with atomoxetine pre-
treatment dose, F(5, 70) = 8.51, p < .001. Specifically, 3 and 
10 mg/kg atomoxetine pretreatment suppressed chamber ac-
tivity to a level consistent with the saline baseline (Fisher’s 
LSD = .056). Together, these results indicate that pretreatment 
with 1 mg/kg atomoxetine partially blocks the cuing effects 
of nicotine (0.2 mg/kg) without blocking nicotine-induced 
hyperactivity. 
Discussion
The present report replicated past research from our lab-
oratory demonstrating that the interoceptive effects of nico-
tine can serve as a CS in a Pavlovian appetitive discrimination 
task (Besheer et al., 2004; Bevins & Palmatier, 2004; Bevins 
et al., 2007; Murray & Bevins, 2007; Wilkinson et al., 2006). 
The current research extends these previous findings by (a) 
demonstrating that cocaine and methylphenidate partially sub-
stitute for nicotine as a CS, (b) showing that bupropion par-
tially substitutes for a lower dose of nicotine than previously 
studied, and (c) finding that atomoxetine does not substitute 
for nicotine but blocks the CR evoked by the nicotine CS, as 
well as nicotine-induced motor activity at the higher doses. 
Of note, two commonly prescribed ADHD medications (i.e., 
methylphenidate and bupropion) were able to evoke nicotine-
appropriate responding. Given the propensity for people di-
agnosed with ADHD to abuse tobacco products, this research 
has important implications for pharmacotherapy development 
focused on nicotine dependence in this clinical subpopulation 
(addressed later).
Of the drugs used to treat ADHD, bupropion and meth-
ylphenidate produced some nicotine-appropriate respond-
ing, whereas atomoxetine did not. This result is not surprising 
given the shared neuropharmacological mechanisms between 
bupropion, methylphenidate, and nicotine. In general, each 
of these drugs increases dopaminergic neurotransmission in 
brain reward pathways. More specifically, bupropion elevates 
dopamine concentrations in the nucleus accumbens and stri-
atum by inhibiting dopamine and norepinephrine reuptake 
(Ascher et al., 1995; Miller, Sumithran, & Dwoskin, 2002; 
Nomikos et al., 1992). Methylphenidate increases dopamine 
and norepinephrine in the prefrontal cortex, nucleus accum-
bens, and striatum by blocking reuptake mechanisms (By-
master et al., 2002; Kuczenski, & Segal, 1997). Nicotine indi-
rectly increases dopaminergic neurotransmission by activating 
nicotinic acetylcholine receptors located on dopamine projec-
tions from the ventral tegmental area (Corrigall, Coen, & Ad-
amson, 1994; Stolerman & Shoaib, 1991). On the other hand, 
atomoxetine does not increase synaptic dopamine in brain re-
gions associated with reward. More specifically, atomoxetine 
increases extracellular norepinephrine and dopamine in the 
prefrontal cortex but not in the nucleus accumbens or stria-
tum by inhibiting norepinephrine reuptake (Bymaster et al., 
2002). Differences between cortical and subcortical dopami-
nergic neurotransmission suggest that atomoxetine lacks the 
abuse liability associated with psychostimulant drugs. In-
deed, atomoxetine is not self-administered in animal mod-
els of drug taking that are predictive of human drug abuse li-
ability (Gasior, Bergman, Kallman, & Paronis, 2005; Wee & 
Woolverton, 2004). In contrast, bupropion, methylphenidate, 
and nicotine are self-administered in laboratory animals (Cor-
Figure 4. Mean (±SEM) dipper entries (left graph) and chamber activity (right graph) during antago-
nism testing with atomoxetine (n = 15). *Significantly different from 0.2 mg/kg nicotine, p < .05. +Sig-
nificantly different from saline, p < .05.
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rigall et al., 1994; Gasior et al., 2005; Lamb & Griffiths, 1990; 
Rauhut, Mullins, Dwoskin, & Bardo, 2002; Tella, Ladenheim, 
& Cadet, 1997).
We also tested whether the dopamine reuptake inhibitors 
cocaine and GBR 12909 would substitute for nicotine as a CS 
to assess drugs with varying affinity for the dopamine trans-
porter. Cocaine partially substituted for the CS effects of nic-
otine, whereas GBR 12909 did not produce a statistically sig-
nificant increase in conditioned responding. These drugs, as 
well as bupropion and methylphenidate, block dopamine 
reuptake with varying affinity. More specifically, in rank or-
der from the weakest to strongest, affinity for the dopamine 
transporter is bupropion < cocaine < methylphenidate < GBR 
12909 (Katz et al., 2000). It is interesting to note that this rank 
ordering matches the substitution pattern of these drugs for 
the CS properties of nicotine in the current study. That is, the 
drugs with the weakest affinity for the dopamine transporter 
appeared to substitute for the nicotine CS more readily than 
the drugs with stronger binding affinities. This finding could 
indicate that specific blockade of the dopamine transporter 
does not result in an interoceptive cue similar to the one ex-
perienced when nicotine is present in the central nervous sys-
tem. More likely, a mixture of dopamine reuptake inhibition 
in combination with actions at norepinephrine, nicotinic ace-
tylcholine, and/or serotonin receptors may better simulate the 
interoceptive CS effects of nicotine.
General chamber activity was measured throughout the en-
tire experiment. The most notable observation from these data 
is that a difference in dipper entries was not necessarily paral-
leled in the general chamber activity. For example, during ac-
quisition, dipper entries and chamber activity were substan-
tially higher during nicotine than during saline sessions. In 
contrast, during substitution testing, drugs that increased mo-
tor activity (e.g., GBR 12909 at 10, 20, and 30 mg/kg) did not 
always increase dipper entries. This dissociation is method-
ologically important because it indicates that our measure of 
conditioned responding (i.e., goal tracking) is not attributable 
to nonspecific motor alterations of the test compounds.
The 1 mg/kg atomoxetine dose partially blocked the cu-
ing effects of nicotine without altering the locomotor enhanc-
ing effect of nicotine. Additionally, higher atomoxetine doses 
(i.e., 3 and 10 mg/kg) blocked nicotine-induced motor ac-
tivity as well as the nicotine-evoked CR. Thus, atomoxetine 
blocked both the CS and motor-activating effects of nicotine, 
with the CS effects being more sensitive to antagonism. The 
exact mechanisms by which atomoxetine antagonized these 
nicotine-related behaviors will require further investigation. 
However, research suggests a possible role of cortical norepi-
nephrine, dopamine, and/or acetylcholine efflux (Tzavara et 
al., 2006). One suggestion for the procholinergic property is 
that converging dopamine and norepinephrine neurons modu-
late cortical acetylcholine release at the nucleus basalis (Tza-
vara et al., 2006). Thus, atomoxetine indirectly increases ace-
tylcholine levels by activating α − 1 norepinephrine receptors 
and/or dopamine D1 receptors (Tzavara et al., 2006). Of note, 
reboxetine, another selective norepinephrine reuptake inhib-
itor, produced the same cortical acetylcholine efflux (Tza-
vara et al., 2006) and also inhibits nicotinic acetylcholine re-
ceptors (nAChRs; Miller, Wong, Chesnut, & Dwoskin, 2002). 
Albeit speculative, if atomoxetine shares the ability to inhibit 
nAChRs with reboxetine, one possible explanation for atom-
oxetine’s impact on nicotine-mediated behaviors in the pres-
ent experiment may be its antagonism of nAChRs.
An alternative explanation for blockade of the CS effects 
of nicotine is that nicotine and atomoxetine administered to-
gether produce an interoceptive cue that is distinct from that 
produced by nicotine alone. Both nicotine and atomoxetine 
separately increase noradrenergic neurotransmission in the 
hippocampus that, when combined, may result in overstimu-
lation of norepinephrine neurons (Fu, Matta, James, & Sharp, 
1998; Gould et al., 2005; P. E. Potter, Thorne, & Gaughan, 
1997; Swanson et al., 2006). Thus, conditioned responding 
to nicotine would decrease if the nicotine cue was progres-
sively changed with increases in atomoxetine dose. In previ-
ous drug discrimination studies atomoxetine substituted for 
several different drugs, which lends feasibility to this sugges-
tion. For instance, atomoxetine partially substituted (i.e., 33% 
to 50% responding) for methylphenidate in a human drug 
discrimination study (Lile, Stoops, Durell, Glaser, & Rush, 
2006). In studies with rats, atomoxetine fully substituted for 
a low dose of cocaine and partially substituted for the potas-
sium channel blocker 4-aminopyridine (Brandsgaard, Barrett, 
& Rosenzweig-Lipson, 2000; Terry, Witkin, & Katz, 1994). 
However, our enthusiasm for this account is somewhat dimin-
ished because changes in the nicotine cue would not neces-
sarily account for the concurrent blockade of nicotine-induced 
chamber activity. Further, conditioned responding was only 
partially blocked, whereas chamber activity was fully antago-
nized to saline levels.
Methylphenidate, bupropion, and atomoxetine are pre-
scribed for the treatment of ADHD. Of these drugs, atom-
oxetine is the only drug that does not increase dopamine re-
lease in the mesolimbic dopamine system. In fact, volunteers 
with a history of light drug use, including exposure to vari-
ous psychostimulant drugs, reported that the subjective ef-
fects of atomoxetine were “bad” or “sick” rather than “good” 
or “stimulating,” indicating little or no abuse potential (Heil et 
al., 2002). Thus, atomoxetine provides a nonstimulant phar-
macological treatment for ADHD. As mentioned previously, 
ADHD is a risk factor for initiation of cigarette smoking (Mil-
berger et al., 1997). Of the ADHD drugs tested in the present 
study, atomoxetine was the only drug that did not at least par-
tially substitute for the interoceptive stimulus effects of nico-
tine. However, atomoxetine did block the interoceptive stim-
ulus properties and locomotor activating effects of nicotine. 
For these reasons, we suggest atomoxetine may have addi-
tional benefits for patients with ADHD who are also addicted 
to nicotine. Indeed, this suggestion was recently posited by 
Gould and colleagues (see Davis & Gould, 2007; Gould et al., 
2005). In further support of this notion, a norepinephrine reup-
take inhibitor (i.e., reboxetine) was reported to decrease nico-
tine self-administration in rats (Rauhut, Mullins, Dwoskin, & 
508 Reichel, linkugel, & Bevins in ExpErimEntal and CliniCal psyChopharmaCology, 15 (2007)
Bardo, 2002). Thus, there may be clinical utility for atomox-
etine as a smoking prevention and/or intervention aid for pa-
tients diagnosed with ADHD. The current findings merit fur-
ther preclinical investigations of atomoxetine in the treatment 
of nicotine addiction.
References
Ascher, J. A., Cole, J. O., Colin, J. N., Feighner, J. P., Ferris, R. M., 
Fibiger, H. C., et al. (1995). Bupropion: A review of its mecha-
nism of antidepressant activity. Journal of Clinical Psychiatry, 
56, 395–401.
Besheer, J., Palmatier, M. I., Metschke, D. M., & Bevins, R. A. 
(2004). Nicotine as a signal for the presence or absence of su-
crose reward: A Pavlovian drug appetitive conditioning prepara-
tion in rats. Psychopharmacology, 172, 108–117.
Bevins, R. A., & Palmatier, M. I. (2004). Extending the role of asso-
ciative learning processes in nicotine addiction. Behavioral and 
Cognitive Neuroscience Reviews, 3, 143–158.
Bevins, R. A., Penrod, R. D., & Reichel, C. M. (2007). Nicotine does 
not produce state-dependent effects on learning in a Pavlovian 
appetitive goal tracking task with rats. Behavioural Brain Re-
search, 177, 134–141.
Boakes, R. A. (1977). Performance on learning to associate a stimu-
lus with positive reinforcement. In H.Davis & H. M. B.Hurwitz 
(Eds.), Operant-Pavlovian interactions (pp. 67–101). Hillsdale, 
NJ: Erlbaum.
Brandsgaard, R., Barrett, J. E., & Rosenzweig-Lipson, S. (2000). 
Pharmacological characterization of the discriminative stimulus 
effects of the potassium channel blocker 4-aminopyridine in rats. 
Journal of Pharmacology and Experimental Therapeutics, 295, 
295–391.
Bymaster, F. P., Katner, J. S., Nelson, D. L., Hemrick-Luecke, S. K., 
Threlkeld, P. G., Heiligenstein, J. H., et al. (2002). Atomoxetine 
increases extracellular levels of norepinephrine and dopamine in 
prefrontal cortex of rat: A potential mechanism for efficacy in at-
tention deficit/hyperactivity disorder. Neuropsychopharmacol-
ogy, 27, 699–711.
Clements, K., Glautier, S., Stolerman, I. P., White, J.-A. W., & Tay-
lor, C. (1996). Classical conditioning in humans: Nicotine as CS 
and alcohol as US. Human Psychopharmacology, 11, 85–95.
Corrigall, W. A., Coen, K. M., & Adamson, K. L. (1994). Self-ad-
ministered nicotine activates the mesolimbic dopamine sys-
tem through the ventral tegmental area. Brain Research, 653, 
278–284.
Davis, J. A., & Gould, T. J. (2007). Atomoxetine reverses nicotine 
withdrawal-associated deficits in contextual fear conditioning. 
Neuropsychopharmacology, 32, 2011–2019.
Davis, J. A., James, J. R., Siegel, S. J., & Gould, T. J. (2005). With-
drawal from chronic nicotine administration impairs contextual 
fear conditioning in C57BL/6 mice. Journal of Neuroscience, 25, 
8708–8713.
de Leon, J., & Diaz, F. J. (2005). A meta-analysis of worldwide stud-
ies demonstrates an association between schizophrenia and to-
bacco smoking behaviors. Schizophrenia Research, 76, 135–157.
Desai, R. I., Barber, D. J., & Terry, P. (2003). Dopaminergic and cho-
linergic involvement in the discriminative stimulus effects of nic-
otine and cocaine in rats. Psychopharmacology, 167, 335–343.
Di Chiara, G. (1999). Drug addiction as dopamine-dependent asso-
ciative learning disorder. European Journal of Pharmacology, 
375, 13–30.
Farwell, B. J., & Ayres, J. J. B. (1979). Stimulus-reinforcer and re-
sponse-reinforcer relations in the control of conditioned appeti-
tive headpoking (“goal tracking”) in rats. Learning and Motiva-
tion, 10, 295–312.
Fu, Y., Matta, S. G., James, T. J., & Sharp, B. M. (1998). Nicotine-in-
duced norepinephrine release in the rat amygdala and hippocam-
pus is mediated through brainstem nicotinic cholinergic recep-
tors. Journal of Pharmacology and Experimental Therapeutics, 
284, 1188–1196.
Gasior, M., Bergman, J., Kallman, M. J., & Paronis, C. A. (2005). 
Evaluation of the reinforcing effects of monoamine reuptake in-
hibitors under a concurrent schedule of food and i.v. drug de-
livery in rhesus monkeys. Neuropsychopharmacology, 30, 
758–764.
Geier, A., Mucha, R. F., & Pauli, P. (2000). Appetitive nature of drug 
cues confirmed with physiological measures in a model using 
pictures of smoking. Psychopharmacology, 150, 283–291.
Glassman, A. H., Helzer, J. E., Covey, L. S., Cottler, L. B., Stetner, 
F., Tipp, J. E., et al. (1990). Smoking, smoking cessation, and 
major depression. Journal of the American Medical Association, 
264, 1546–1549.
Gould, T. J., Rukstalis, M., & Lewis, M. C. (2005). Atomoxetine 
and nicotine enhance prepulse inhibition of acoustic startle in 
C57BL/6 mice. Neuroscience Letters, 377, 85–90.
Heil, S. H., Holmes, H. W., Bickel, W. K., Higgins, S. T., Badger, G. 
J., Laws, H. F., & Faries, D. E. (2002). Comparison of the sub-
jective, physiological, and psychomotor effects of atomoxetine 
and methylphenidate in light drug users. Drug and Alcohol De-
pendence, 67, 149–156.
Katz, J. L., Izenwasser, S., & Terry, P. (2000). Relationships among 
dopamine transporter affinities and cocaine-like discriminative-
stimulus effects. Psychopharmacology, 148, 90.
Kuczenski, R., & Segal, D. S. (1997). Effects of methylphenidate 
on extracellular dopamine, serotonin, and norepinephrine: Com-
parison with amphetamine. Journal of Neurochemistry, 68, 
2032–2037.
Lamb, R. J., & Griffiths, R. R. (1990). Self-administration in ba-
boons and the discriminative stimulus effects in rats of bupro-
pion, nomifensine, diclofensine and imipramine. Psychopharma-
cology, 102, 183–190.
Lazev, A. B., Herzog, T. A., & Brandon, T. H. (1999). Classical con-
ditioning of environmental cues to cigarette smoking. Experi-
mental and Clinical Psychopharmacology, 7, 56–63.
Lile, J. A., Stoops, W. W., Durell, T. M., Glaser, P. E. A., & Rush, C. 
R. (2006). Discriminative-stimulus, self-reported, performance, 
and cardiovascular effects of atomoxetine in methylphenidate-
trained humans. Experimental and Clinical Psychopharmacol-
ogy, 14, 136–147.
Mansbach, R. S., Rovetti, C. C., & Freedland, C. S. (1998). The role 
of monoamine neurotransmitter systems in the nicotine discrimi-
native stimulus. Drug and Alcohol Dependence, 52, 125–134.
Mattiuz, E. L., Ponsler, G. D., Barbuch, R. J., Wood, P. G., Mullen, 
J. H., Shugert, R. L., et al. (2003). Disposition and metabolic fate 
of atomoxetine hydrochloride: Pharmacokinetics, metabolism, 
and excretion in the Fisher 344 rat and beagle dog. Journal of 
Pharmacology and Experimental Therapeutics, 31, 88–97.
nicotine as a conditioned stimulus: attention-deficit/hypeRactivity disoRdeR medications  509
Milberger, S., Biederman, J., Faraone, S. V., Chen, L., & Jones, J. 
(1997). ADHD is associated with early initiation of cigarette 
smoking in children and adolescents. Journal of the American 
Academy of Child and Adolescent Psychiatry, 36, 37–44.
Miller, D. K., Sumithran, S. P., & Dwoskin, L. P. (2002). Bupropion 
inhibits nicotine-evoked [3H]overflow from rat striatal slices 
preloaded with [3H]dopamine and from rat hippocampal slices 
preloaded with [3H]norepinephrine. Journal of Pharmacological 
and Experimental Therapeutics, 302, 1113–1122.
Miller, D. K., Wong, E. H. F., Chesnut, M. D., & Dwoskin, L. P. 
(2002). Reboxetine: Functional inhibition of monoamine trans-
porters and nicotinic acetylcholine receptors. Journal of Phar-
macological and Experimental Therapeutics, 302, 687–695.
Morris, C. D., Giese, A. A., Turnbull, J. J., Dickinson, M., & John-
son-Nagel, N. (2006). Predictors of tobacco use among persons 
with mental illnesses in a statewide population. Psychiatric Ser-
vices, 57, 1035–1038.
Murray, J. E., & Bevins, R. A. (2007). Behavioral and neuropharma-
cological characterization of nicotine as a conditioned stimulus. 
European Journal of Pharmacology, 561, 91–104.
National Research Council (1996). Guide for the care and use of lab-
oratory animals. Washington, DC: National Academy Press.
Nomikos, G. G., Damsma, G., Wenkstern, D., & Fibiger, H. C. 
(1992). Effects of chronic bupropion on interstitial concentra-
tions of dopamine in rat nucleus accumbens and striatum. Neuro-
psychopharmacology, 7, 7–14.
Pomerleau, C. S., Downey, K. K., Snedecor, S. M., Mehringer, A. 
M., Marks, J. L., & Pomerleau, O. F. (2003). Smoking patterns 
and abstinence effects in smokers with no ADHD, childhood 
ADHD, and adult ADHD symptomatology. Addictive Behaviors, 
28, 1149–1157.
Pomerleau, C. S., Marks, J. L., & Pomerleau, O. F. (2000). Who gets 
what symptom? Effects of psychiatric cofactors and nicotine de-
pendence on patterns of smoking withdrawal symptomatology. 
Nicotine & Tobacco Research, 2, 275–280.
Potter, A. S., & Newhouse, P. A. (2004). Effects of acute nicotine ad-
ministration on behavioral inhibition in adolescents with atten-
tion-deficit/hyperactivity disorder. Psychopharmacology, 176, 
183–194.
Potter, P. E., Thorne, B., & Gaughan, C. (1997). Modulation of hip-
pocampal norepinephrine release by cholinergic agonists is al-
tered by AF64A lesion. Brain Research Bulletin, 42, 153–160.
Pritchard, W. S., Robinson, J. H., Guy, T. D., Davis, R. A., & Stiles, 
M. F. (1996). Assessing the sensory role of nicotine in cigarette 
smoking. Psychopharmacology, 127, 55–62.
Rauhut, A. S., Mullins, S. N., Dwoskin, L. P., & Bardo, M. T. (2002). 
Reboxetine: Attenuation of intravenous nicotine self-administra-
tion in rats. Journal of Pharmacological and Experimental Ther-
apeutics, 303, 664–672.
Rose, J. E., & Levin, E. D. (1991). Inter-relationships between con-
ditioned and primary reinforcement in the maintenance of ciga-
rette smoking. British Journal of Addiction, 86, 605–609.
Stolerman, I. P., & Shoaib, M. (1991). The neurobiology of tobacco 
addiction. Trends in Pharmacological Sciences, 12, 467–473.
Swanson, C. J., Perry, K. W., Koch-Krueger, S., Katner, J., Svensson, 
D. A., & Bymaster, F. P. (2006). Effect of the attention deficit/hy-
peractivity disorder drug atomoxetine on extracellular concentra-
tions of norepinephrine and dopamine in several regions of the 
rat. Neuropharmacology, 50, 755–760.
Tella, S. R., Ladenheim, B., & Cadet, J. L. (1997). Differential reg-
ulation of dopamine transporter after chronic self-administration 
of bupropion and nomifensine. Journal of Pharmacology and 
Experimental Therapeutics, 281, 508–513.
Terry, P., Witkin, J. M., & Katz, J. K. (1994). Pharmacological char-
acterization of the novel discriminative stimulus effects of a low 
dose of cocaine. Journal of Pharmacology and Experimental 
Therapeutics, 271, 1041–1048.
Troisi, J. R., II. (2006). Pavlovian-instrumental transfer of the dis-
criminative stimulus effects of nicotine and ethanol in rats. Psy-
chological Record, 56, 499–512.
Tzavara, E. T., Bymaster, F. P., Overshiner, C. D., Davis, R. J., Perry, 
K. W., Wolff, M., et al. (2006). Procholinergic and memory en-
hancing properties of the selective norepinephrine uptake inhibi-
tor atomoxetine. Molecular Psychiatry, 11, 187–195.
Wee, S., & Woolverton, W. L. (2004). Evaluation of the reinforc-
ing effects of atomoxetine in monkeys: Comparison to methyl-
phenidate and desipramine. Drug and Alcohol Dependence, 75, 
271–276.
Wilkinson, J. L., Murray, J. E., Li, C., Wiltgen, S. M., Penrod, R. D., 
Berg, S. A., et al. (2006). Interoceptive Pavlovian conditioning 
with nicotine as the conditional stimulus varies as a function of 
the number of conditioning trials and unpaired sucrose deliver-
ies. Behavioural Pharmacology, 17, 161–172.
Williams, J. M., & Ziedonis, D. (2004). Addressing tobacco among 
individuals with a mental illness or an addiction. Addictive Be-
haviors, 29, 1067–1083.
